Tazemetostat
Desmoplastic Small Round Cell Tumor (DSRCT)
Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Desmoplastic Small Round Cell Tumor (DSRCT) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | B |
Fludarabine St. Jude Children's Research Hospital | Phase 2 | B |
Imatinib National Cancer Institute (NCI) | Phase 2 | B |
ETOPOSIDE M.D. Anderson Cancer Center | Phase 2 | CCC |
Evomela M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 30 →
Same molecule, other indications
Tazemetostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →